Michael Soliman, chairman of U.S. Sen. Bob Menendez’s reelection campaign, attacked Republican challenger Bob Hugin over alleged price gouging on cancer medications after the latter made his tax returns available to reporters in a restricted review session.
“While there is nothing wrong with being rich, Bob Hugin’s getting rich by ripping off cancer patients is despicable,” Soliman said in statement Monday. “With a salary, bonuses and stock options totaling more than $80 million in just three years, it’s now clear why drug company CEO Bob Hugin thought writing a $280 million check to settle accusations that his company defrauded taxpayers and misled patients was no big deal.”
Hugin’s campaign allowed reporters to review the candidates 2015 and 2016 tax returns for two hours on Monday without any access to electronics to look up or copy information from the documents. The restrictions severely limited the analysis of Hugin’s returns.
Still, one thing was clear — Hugin is wealthy. Hugin, former executive chair of the Celgene Corporation, a biotech firm, made $34 million in the two years those tax returns covered, and his Senate financial disclosure form shows him making more than $48 million in 2017 and the early months of 2018.
“Bob Hugin has gotten very, very rich from overcharging cancer patients for the the drugs they depend upon- and apparently he has no shame in showing off how much money he made from doing that,” Soliman said.